目的利用P ich ia p astoris酵母表达系统表达糖基化的肿瘤相关抗原17-1A,为进一步设计肿瘤蛋白疫苗提供研究基础。方法通过RT-PCR从小鼠肾组织中扩增17-1A的cDNA,将其定向克隆到pP ICZαA质粒上,获得重组质粒pP ICZαA-17-1A,测序正确...目的利用P ich ia p astoris酵母表达系统表达糖基化的肿瘤相关抗原17-1A,为进一步设计肿瘤蛋白疫苗提供研究基础。方法通过RT-PCR从小鼠肾组织中扩增17-1A的cDNA,将其定向克隆到pP ICZαA质粒上,获得重组质粒pP ICZαA-17-1A,测序正确后,重组质粒电转化到P ich ia p astoris酵母菌株G S115中,在甲醇诱导下,利用其AOXⅠ基因的α信号肽,分泌表达17-1A抗原糖蛋白,并对获得的蛋白进行SDS-PAGE及W estern b lot分析鉴定。结果构建了pP ICZαA-17-1A重组质粒,通过电转化将目的基因整合入酵母基因组中,重组毕赤酵母表达能够表达17-1A抗原并检测到抗原发生了糖基化。结论能够通过毕赤酵母表达系统稳定表达糖基化的肿瘤相关抗原17-1A。展开更多
The tumor-associated antigen Ep-CAM (17-1A antigen), defined by the murine monoclonal antibody (mAb) 17-1A, has been identified as a 42-kD glycoprotein. The mAb 17-1A has been used for immunotherapy of colorectal can...The tumor-associated antigen Ep-CAM (17-1A antigen), defined by the murine monoclonal antibody (mAb) 17-1A, has been identified as a 42-kD glycoprotein. The mAb 17-1A has been used for immunotherapy of colorectal cancer. We obtained mAb 19F4 using a synthetic peptide containing antigen determinants of 17-1A antigen. The mAb 19F4 can bind the corresponding dominants of the 17-1A antigen in ELISA. Western-blot analysis demonstrated that mAb 19F4 recognized a 50-kD protein from cell lysates of MCF-7 (breast cancer cell line). Both mAb 19F4 and 17-1A detected a 42-kD protein in the cell lysates of HT-29 (colorectal cancer cell line). The results suggest that new members of the tumor-associated antigen family 17-1A may exist.展开更多
AIM To investigate the antitumor effects and underlying mechanisms of(17 R,18 R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt(YLG-1)-induced photodynamic therapy(PDT) on pancreatic cancer in vitro and in v...AIM To investigate the antitumor effects and underlying mechanisms of(17 R,18 R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt(YLG-1)-induced photodynamic therapy(PDT) on pancreatic cancer in vitro and in vivo.METHODS YLG-1 is a novel photosensitizer extracted from spirulina. Its phototoxicity, cellular uptake and localization, as well as its effect on reactive oxygen species(ROS) production, apoptosis, and expression of apoptosis-associated proteins were detected in vitro. An in vivo imaging system(IVIS), the Lumina K imaging system, and mouse models of subcutaneous Panc-1-bearing tumors were exploited to evaluate the drug delivery pathway and pancreatic cancer growth in vivo.RESULTS YLG-1 was localized to the mitochondria, and the appropriate incubation time was 6 h. Under 650 nm light irradiation, YLG-1-PDT exerted a potent cytotoxic effect on pancreatic cancer cells in vitro, which could be abolished by the ROS scavenger N-acetyl-L-cysteine(NAC). The death mode caused by YLG-1-PDT was apoptosis, accompanied by upregulated Bax and cleaved Caspase-3 and decreased Bcl-2 expression. The results from the IVIS images suggested that the optimal administration route was intratumoral(IT) injection and that the best time to conduct YLG-1-PDT was 2 h post-IT injection. Consistent with the results in vitro, YLG-1-PDT showed great growth inhibition effects on pancreatic cancer cells in a mouse model.CONCLUSION YLG-1 is a potential photosensitizer for pancreatic cancer PDT via IT injection, the mechanisms of which are associated with inducing ROS and promoting apoptosis.展开更多
文摘目的利用P ich ia p astoris酵母表达系统表达糖基化的肿瘤相关抗原17-1A,为进一步设计肿瘤蛋白疫苗提供研究基础。方法通过RT-PCR从小鼠肾组织中扩增17-1A的cDNA,将其定向克隆到pP ICZαA质粒上,获得重组质粒pP ICZαA-17-1A,测序正确后,重组质粒电转化到P ich ia p astoris酵母菌株G S115中,在甲醇诱导下,利用其AOXⅠ基因的α信号肽,分泌表达17-1A抗原糖蛋白,并对获得的蛋白进行SDS-PAGE及W estern b lot分析鉴定。结果构建了pP ICZαA-17-1A重组质粒,通过电转化将目的基因整合入酵母基因组中,重组毕赤酵母表达能够表达17-1A抗原并检测到抗原发生了糖基化。结论能够通过毕赤酵母表达系统稳定表达糖基化的肿瘤相关抗原17-1A。
基金Supported by the National Key Basic Research SpecificFunds(No.G19990 75 60 7) and the National ScienceFoundation for Outstanding Young Scientist of China(No.3 0 0 2 5 0 3 8)
文摘The tumor-associated antigen Ep-CAM (17-1A antigen), defined by the murine monoclonal antibody (mAb) 17-1A, has been identified as a 42-kD glycoprotein. The mAb 17-1A has been used for immunotherapy of colorectal cancer. We obtained mAb 19F4 using a synthetic peptide containing antigen determinants of 17-1A antigen. The mAb 19F4 can bind the corresponding dominants of the 17-1A antigen in ELISA. Western-blot analysis demonstrated that mAb 19F4 recognized a 50-kD protein from cell lysates of MCF-7 (breast cancer cell line). Both mAb 19F4 and 17-1A detected a 42-kD protein in the cell lysates of HT-29 (colorectal cancer cell line). The results suggest that new members of the tumor-associated antigen family 17-1A may exist.
基金Supported by National Natural Science Foundation of China,No.81472844
文摘AIM To investigate the antitumor effects and underlying mechanisms of(17 R,18 R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt(YLG-1)-induced photodynamic therapy(PDT) on pancreatic cancer in vitro and in vivo.METHODS YLG-1 is a novel photosensitizer extracted from spirulina. Its phototoxicity, cellular uptake and localization, as well as its effect on reactive oxygen species(ROS) production, apoptosis, and expression of apoptosis-associated proteins were detected in vitro. An in vivo imaging system(IVIS), the Lumina K imaging system, and mouse models of subcutaneous Panc-1-bearing tumors were exploited to evaluate the drug delivery pathway and pancreatic cancer growth in vivo.RESULTS YLG-1 was localized to the mitochondria, and the appropriate incubation time was 6 h. Under 650 nm light irradiation, YLG-1-PDT exerted a potent cytotoxic effect on pancreatic cancer cells in vitro, which could be abolished by the ROS scavenger N-acetyl-L-cysteine(NAC). The death mode caused by YLG-1-PDT was apoptosis, accompanied by upregulated Bax and cleaved Caspase-3 and decreased Bcl-2 expression. The results from the IVIS images suggested that the optimal administration route was intratumoral(IT) injection and that the best time to conduct YLG-1-PDT was 2 h post-IT injection. Consistent with the results in vitro, YLG-1-PDT showed great growth inhibition effects on pancreatic cancer cells in a mouse model.CONCLUSION YLG-1 is a potential photosensitizer for pancreatic cancer PDT via IT injection, the mechanisms of which are associated with inducing ROS and promoting apoptosis.